Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: A Technical Note on Scale-Up
DOI:
https://doi.org/10.5281/zenodo.22648994Keywords:
Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor, Translational medicine; Evidence synthesis, Clinical implementation; Health services researchAbstract
Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for nanoparticle
formulation of a poorly soluble kinase inhibitor, spanning analytical, clinical, implementation, governance, and economic
dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical considerations
relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence
currently available, rather than uniform adoption or avoidance
References
Alvez D, Dumitrescu A, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.3389/fdgth.2026.1763884
Brankovic K, Kowalczyk B, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.2196/48297
Castellani R, Ristic C, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1007/s00330-025-12031-z
Dumitrescu A, Andric D, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1699005
Eriksdottir B, Brankovic E, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3389/fdgth.2026.1834800
Farkas I, Ionescu F, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.2196/69678
Grabowski P, Petrescu G, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.7759/cureus.46454
Hendriksen W, Wojcik H, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1016/j.ssci.2025.107028
Ionescu F, Foscarini I, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.2196/48633
Jankowiak G, Grabowski J, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1371/journal.pone.0305949
Kowalczyk N, Novotna K, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1371/journal.pdig.0000514
Lindqvist U, Urbanek L, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.17219/acem/208596
Marchetti D, Doncheva M, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.7759/cureus.104086
Novotna E, Eriksdottir N, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1038/s41746-023-00852-5
Ostrowski L, Lindqvist O, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1016/j.mayocpiqo.2022.09.004
Petrescu S, Szabo P, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1177/08404704241291226
Quintero B, Balogh Q, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1093/medlaw/fwad013
Ristic C, Castellani R, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/89834
Szabo J, Jankowiak S, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1007/s10916-024-02104-9
Tarasov Q, Quintero T, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3389/fdgth.2026.1896184
Urbanek Z, Zielinski U, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3390/diagnostics15162117
Vasquez A, Alvez V, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.4103/jrpp.jrpp_20_65
Wojcik H, Hendriksen W, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.3389/fdgth.2026.1763884
Zielinski O, Ostrowski Z, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.2196/48297
Andric V, Vasquez A, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1007/s00330-025-12031-z
Balogh E, Emmerich B, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1699005
Chiriac F, Farkas C, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3389/fdgth.2026.1834800
Doncheva M, Marchetti D, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a validation study". Trials 22(2017): 377-383. DOI: 10.2196/69678
Emmerich T, Tarasov E, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.7759/cureus.46454
Foscarini C, Chiriac F, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1016/j.ssci.2025.107028
Alvez D, Dumitrescu A, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.2196/48633
Brankovic K, Kowalczyk B, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1371/journal.pone.0305949
Castellani R, Ristic C, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1371/journal.pdig.0000514
Dumitrescu A, Andric D, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.17219/acem/208596
Eriksdottir B, Brankovic E, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.7759/cureus.104086
Farkas I, Ionescu F, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1038/s41746-023-00852-5
Grabowski P, Petrescu G, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1016/j.mayocpiqo.2022.09.004
Hendriksen W, Wojcik H, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1177/08404704241291226
Ionescu F, Foscarini I, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1093/medlaw/fwad013
Jankowiak G, Grabowski J, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/89834
Kowalczyk N, Novotna K, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1007/s10916-024-02104-9
Lindqvist U, Urbanek L, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3389/fdgth.2026.1896184
Marchetti D, Doncheva M, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3390/diagnostics15162117
Novotna E, Eriksdottir N, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.4103/jrpp.jrpp_20_65
Ostrowski L, Lindqvist O, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.3389/fdgth.2026.1763884
Petrescu S, Szabo P, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.2196/48297
Quintero B, Balogh Q, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1007/s00330-025-12031-z
Ristic C, Castellani R, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1699005
Szabo J, Jankowiak S, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3389/fdgth.2026.1834800
Tarasov Q, Quintero T, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.2196/69678
Urbanek Z, Zielinski U, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.7759/cureus.46454
Vasquez A, Alvez V, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1016/j.ssci.2025.107028
Wojcik H, Hendriksen W, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.2196/48633
Zielinski O, Ostrowski Z, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1371/journal.pone.0305949
Andric V, Vasquez A, et al. "Nanoparticle Formulation of a Poorly Soluble Kinase Inhibitor: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1371/journal.pdig.0000514
